Search results for "Total lesion glycolysis"

showing 1 items of 1 documents

Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT

2021

Despite the promising results of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) in metastatic castration-resistant prostate cancer (mCRPC), some patients show worsening disease during PSMA-RLT. We investigated the value of combined [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging in this setting. In n = 29 mCRPC patients with worsening disease after a median of four cycles of [177Lu]Lu-PSMA-617 RLT, combined [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging was performed to detect [18F]FDG-avid lesions with low or no PSMA expression (mismatch lesions). To evaluate prognostic implication of mismatch, survival analyses regarding presence, location, and [18F]FDG PET-derived para…

radioligand therapy; PSMA; FDG; PET/CT; mismatch; metastatic castration-resistant prostate cancerCancer Researchmedicine.medical_specialtyFDGPET/CTUrology610Diseaseurologic and male genital diseasesMetastasisProstate cancerPSMAmedicineRC254-282Membrane antigenPET-CTbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensPet imagingMetabolic tumor volumemedicine.diseaseradioligand therapyTotal lesion glycolysismetastatic castration-resistant prostate cancerOncologybusinessmismatchCancers
researchProduct